15 Jan StimulusBio
Andries Zijlstra, Ph.D., Chief Technology Officer
April 29 | 4:15pm | Salone dei Cavalieri, Section 1
Houston, TX,
(Private)
StimulusBio accelerates the development of cell and gene therapies through innovative product solutions that reduce the time and cost of therapeutic development. Our scalable, easy-to-integrate technologies drive consistency, enhance cellular expansion, and streamline complex workflows empowering researchers and manufacturers to more efficiently translate discoveries into clinical solutions. The StimulusBio product pipeline centers around a programmable cellular interface ( sbPCI ) that enables precise control over cellular environments, supporting reproducible outcomes and faster iteration in both research and clinical translation. In addition to tools development, our scientists are working to realize applications of sbPCI in therapeutic solutions. By combining commercial expertise and scientific innovation, StimulusBio is committed to ensuring that our foundational sbPCI technology successfully enables the leap from the bench to the bedside.
